Want to see NERV full AI Analyst Report?
NERV Stock Chart & Stats
$6.73
-$0.09(-3.83%)
At close: 4:00 PM EST
$6.73
-$0.09(-3.83%)
Day’s Range― - ―
52-Week Range$1.59 - $12.46
Previous CloseN/A
Volume1.19K
Average Volume (3M)465.60K
Market Cap
$239.93M
Enterprise Value$61.50M
Total Cash (Recent Filing)$78.16M
Total Debt (Recent Filing)$64.96M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 04, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.16
Shares Outstanding46,588,710
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$10.50Price Target Upside56.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Lead AssetMinerva’s roluperidone is in a pivotal Phase 3 program with defined milestone timing to 2027/2028. A successful late-stage readout would materially change the company’s structural profile by creating a commercial asset in a high unmet-need CNS indication, attracting partners or licensing and enabling durable revenue streams beyond R&D funding.
Strengthened Business And Legal LeadershipBringing on an experienced CBO/General Counsel enhances capabilities for financing, strategic partnerships, and FDA interactions. This durable upgrade to transactional and regulatory execution reduces execution risk on complex late‑stage development and commercialization planning, improving odds of successful trials and deal-making.
Improved Corporate Governance FrameworkUpdating charter and bylaws to align with Delaware/SEC norms, adopting exculpation provisions and clarifying forum and proxy mechanics reduces legal and governance friction. That structural clarity supports smoother shareholder relations, lowers litigation risk, and can facilitate future financings or strategic transactions.
Bears Say
No Commercial Revenue; Persistent LossesThe company remains fully R&D-funded with no demonstrated revenue trajectory and recurring operating losses. Over the medium term this limits reinvestment capacity, makes sustaining operations contingent on external capital, and amplifies financial risk if clinical progress stalls or development timelines extend.
Negative Cash Flow And Reliance On Equity FundingConsistently negative operating and free cash flow forces reliance on financings to fund trials. Structural dependence on equity issuance (e.g., ATM program) creates dilution risk and ties program continuity to capital markets access, raising execution risk for multi‑year development timelines common in CNS drug development.
Weakened Balance Sheet And Added LeverageNegative equity plus a new meaningful debt load materially reduce financial flexibility. Elevated leverage increases refinancing sensitivity and going‑concern risk during a multi‑year development cycle, constraining the company’s ability to weather trial delays or higher-than-expected development costs without dilutive financings.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.59 and its highest was $12.46 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $239.93M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Aug 04, 2026 which is in 32 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on May 05, 2026. The company reported -$2.86 earnings per share for the quarter, missing the consensus estimate of -$0.127 by -$2.733.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.19.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 46,588,710 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$2.86 in its last earnings report, missing expectations of -$0.127. Following the earnings report the stock price went down -1.264%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Minerva Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.48%
12-Months-Change
Fundamentals
Return on Equity
359.80%
Trailing 12-Months
Asset Growth
186.68%
Trailing 12-Months
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
NERV Stock 12 Month Forecast
Average Price Target
$10.50
▲(56.02% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
―
Aspire Biopharma Holdings
―
Ownership Overview
1.02%
Insiders
5.20% Mutual Funds
42.92% Other Institutional Investors
44.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---